Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment
Fernando Martinez, Joseph Boscia, Gregory Feldman, Catherine Scott-Wilson, Sally Kilbride, Leonardi Fabbri, Peter M.A. Calverley, Courtney Crim
European Respiratory Journal 2012 40: P2887; DOI:
Fernando Martinez
1Department of Medicine, University of Michigan, Ann Arbor, United States
Joseph Boscia
2Clinical Research, CU Pharmaceutical Research, Union, United States
Gregory Feldman
3Clinical Research, S. Carolina Pharmaceutical Research, Spartanburg, United States
Catherine Scott-Wilson
4Respiratory Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United Kingdom
Sally Kilbride
5Department of Oncology Haematology and Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy
Leonardi Fabbri
6Clinical Science Centre, University Hospital Aintree, Liverpool, United Kingdom
Peter M.A. Calverley
6Clinical Science Centre, University Hospital Aintree, Liverpool, United Kingdom
Courtney Crim
4Respiratory Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United Kingdom
Vol 40 Issue Suppl 56
Table of Contents
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment
Fernando Martinez, Joseph Boscia, Gregory Feldman, Catherine Scott-Wilson, Sally Kilbride, Leonardi Fabbri, Peter M.A. Calverley, Courtney Crim
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2887;
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment
Fernando Martinez, Joseph Boscia, Gregory Feldman, Catherine Scott-Wilson, Sally Kilbride, Leonardi Fabbri, Peter M.A. Calverley, Courtney Crim
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2887;